CIT-话题@MedSci - 梅斯（MedSci）

#CIT#

176篇内容 | 3190人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738616, encodeId=5d451e3861672, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, objectType=article, longId=739076, objectId=83fde390764d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83fde390764d, replyNumber=0, likeNumber=88, createdTime=2022-10-01, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83fde390764d, moduleTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=83fde390764d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738612, encodeId=7b581e38612e4, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Leukemia：Guadecitabine（SGI-110）在外周T细胞淋巴瘤中的综合临床评估, objectType=article, longId=726160, objectId=eab4e261604e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eab4e261604e, replyNumber=0, likeNumber=86, createdTime=2022-07-19, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eab4e261604e, moduleTitle=Leukemia：Guadecitabine（SGI-110）在外周T细胞淋巴瘤中的综合临床评估, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=eab4e261604e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738614, encodeId=aaec1e3861481, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Am J Clin Dermatol ：Deucravacitinib治疗银屑病, objectType=article, longId=736664, objectId=7972e36664b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7972e36664b3, replyNumber=0, likeNumber=98, createdTime=2023-02-27, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7972e36664b3, moduleTitle=Am J Clin Dermatol ：Deucravacitinib治疗银屑病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7972e36664b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738613, encodeId=89971e3861397, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=两年研究数据证实：deucravacitinib治疗中重度斑块状银屑病兼具持久的疗效与一致的安全性, objectType=article, longId=726751, objectId=4e3ee26751c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e3ee26751c7, replyNumber=0, likeNumber=87, createdTime=2022-09-09, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e3ee26751c7, moduleTitle=两年研究数据证实：deucravacitinib治疗中重度斑块状银屑病兼具持久的疗效与一致的安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4e3ee26751c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738608, encodeId=44271e386083e, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Br J Dermatol：Baricitinib 3期临床试验中瘙痒和皮肤严重程度改善对特应性皮炎患者皮肤病生活质量指数的影响, objectType=article, longId=294697, objectId=b3fc29469e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3fc29469e5b, replyNumber=0, likeNumber=97, createdTime=2022-03-02, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3fc29469e5b, moduleTitle=Br J Dermatol：Baricitinib 3期临床试验中瘙痒和皮肤严重程度改善对特应性皮炎患者皮肤病生活质量指数的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b3fc29469e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738615, encodeId=f5941e38615e3, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌, objectType=article, longId=737431, objectId=c616e3743158, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c616e3743158, replyNumber=0, likeNumber=76, createdTime=2022-10-23, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c616e3743158, moduleTitle=J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c616e3743158)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738607, encodeId=febc1e3860762, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, objectType=article, longId=221380, objectId=bb87221380d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb87221380d6, replyNumber=0, likeNumber=103, createdTime=2022-04-20, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb87221380d6, moduleTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bb87221380d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738610, encodeId=b9a41e386100c, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=J Am Acad Dermatol：外用JAK-STAT抑制剂Tofacitinib有效减少非特应性皮炎慢性瘙痒, objectType=article, longId=301104, objectId=bf1030110428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1030110428, replyNumber=0, likeNumber=86, createdTime=2022-04-24, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1030110428, moduleTitle=J Am Acad Dermatol：外用JAK-STAT抑制剂Tofacitinib有效减少非特应性皮炎慢性瘙痒, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bf1030110428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738611, encodeId=f2711e3861123, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性, objectType=article, longId=724945, objectId=a43ee2494583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a43ee2494583, replyNumber=0, likeNumber=91, createdTime=2022-12-05, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a43ee2494583, moduleTitle=Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a43ee2494583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738603, encodeId=32af1e3860304, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Nat Commun：Tofacitinib治疗系统性红斑狼疮的1期临床试验结果, objectType=article, longId=212458, objectId=485a21245897, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=485a21245897, replyNumber=0, likeNumber=96, createdTime=2021-11-03, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=485a21245897, moduleTitle=Nat Commun：Tofacitinib治疗系统性红斑狼疮的1期临床试验结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=485a21245897)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738609, encodeId=31681e38609b7, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=JAMA Dermatol:乌帕替尼（Upadacitinib）治疗中重度特应性皮炎的疗效和安全性, objectType=article, longId=301032, objectId=aa2b30103219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa2b30103219, replyNumber=0, likeNumber=78, createdTime=2022-07-25, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa2b30103219, moduleTitle=JAMA Dermatol:乌帕替尼（Upadacitinib）治疗中重度特应性皮炎的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=aa2b30103219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738606, encodeId=41831e386060b, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, objectType=article, longId=218739, objectId=cba7218e390b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cba7218e390b, replyNumber=0, likeNumber=90, createdTime=2022-04-10, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cba7218e390b, moduleTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cba7218e390b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738597, encodeId=97761e38597ea, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Bioelectricity:电磁场可阻碍乳腺癌转移扩散!, objectType=article, longId=208639, objectId=ae76208639bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae76208639bc, replyNumber=0, likeNumber=72, createdTime=2021-04-06, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae76208639bc, moduleTitle=Bioelectricity:电磁场可阻碍乳腺癌转移扩散!, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ae76208639bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738604, encodeId=fc031e386048d, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=J Asthma Allergy：SCIT+dupilumab治疗过敏性鼻炎是否优于单独的SCIT？, objectType=article, longId=216888, objectId=da9121688864, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da9121688864, replyNumber=0, likeNumber=97, createdTime=2021-11-23, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da9121688864, moduleTitle=J Asthma Allergy：SCIT+dupilumab治疗过敏性鼻炎是否优于单独的SCIT？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=da9121688864)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738599, encodeId=24921e3859917, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=City of Hope与Israelita Albert Einstein签署协议以推动拉美地区的癌症治疗, objectType=article, longId=209625, objectId=fb6b20962556, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb6b20962556, replyNumber=0, likeNumber=85, createdTime=2021-11-19, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb6b20962556, moduleTitle=City of Hope与Israelita Albert Einstein签署协议以推动拉美地区的癌症治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fb6b20962556)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738605, encodeId=a9c91e3860520, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Abrocitinib获得CHMP的积极意见，用于治疗成人中重度特应性皮炎, objectType=article, longId=218693, objectId=91f621869309, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91f621869309, replyNumber=0, likeNumber=83, createdTime=2022-01-05, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91f621869309, moduleTitle=Abrocitinib获得CHMP的积极意见，用于治疗成人中重度特应性皮炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=91f621869309)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738587, encodeId=a1f91e385879c, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, objectType=article, longId=202961, objectId=601d202961a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=601d202961a3, replyNumber=0, likeNumber=83, createdTime=2021-09-01, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=601d202961a3, moduleTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=601d202961a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738602, encodeId=5a0f1e3860271, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=2020年的CiteScore指标发布，你了解什么是CiteScore吗？, objectType=article, longId=212367, objectId=d8a221236e4b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8a221236e4b, replyNumber=0, likeNumber=95, createdTime=2022-01-18, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8a221236e4b, moduleTitle=2020年的CiteScore指标发布，你了解什么是CiteScore吗？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d8a221236e4b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738595, encodeId=5a6e1e3859563, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Clin Cancer Res：DNA甲基转移酶抑制剂Guadecitabine联合顺铂和吉西他滨治疗实体恶性肿瘤, objectType=article, longId=207297, objectId=95e820e29758, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95e820e29758, replyNumber=0, likeNumber=93, createdTime=2021-06-17, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95e820e29758, moduleTitle=Clin Cancer Res：DNA甲基转移酶抑制剂Guadecitabine联合顺铂和吉西他滨治疗实体恶性肿瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=95e820e29758)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738601, encodeId=b3b81e386018f, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Lancet：每日1次Upadacitinib单药治疗可显著改善中重度特应性皮炎患者临床症状, objectType=article, longId=211663, objectId=c26d2116637e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c26d2116637e, replyNumber=0, likeNumber=92, createdTime=2022-03-23, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c26d2116637e, moduleTitle=Lancet：每日1次Upadacitinib单药治疗可显著改善中重度特应性皮炎患者临床症状, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c26d2116637e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CIT

2020-05-29

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）

2022-10-01

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Leukemia：Guadecitabine（SGI-110）在外周T细胞淋巴瘤中的综合临床评估

2022-07-19

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Am J Clin Dermatol ：Deucravacitinib治疗银屑病

2023-02-27

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

两年研究数据证实：deucravacitinib治疗中重度斑块状银屑病兼具持久的疗效与一致的安全性

2022-09-09

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Br J Dermatol：Baricitinib 3期临床试验中瘙痒和皮肤严重程度改善对特应性皮炎患者皮肤病生活质量指数的影响

2022-03-02

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌

2022-10-23

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性

2022-04-20

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

J Am Acad Dermatol：外用JAK-STAT抑制剂Tofacitinib有效减少非特应性皮炎慢性瘙痒

2022-04-24

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性

2022-12-05

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Nat Commun：Tofacitinib治疗系统性红斑狼疮的1期临床试验结果

2021-11-03

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

JAMA Dermatol:乌帕替尼（Upadacitinib）治疗中重度特应性皮炎的疗效和安全性

2022-07-25

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见

2022-04-10

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Bioelectricity:电磁场可阻碍乳腺癌转移扩散!

2021-04-06

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

J Asthma Allergy：SCIT+dupilumab治疗过敏性鼻炎是否优于单独的SCIT？

2021-11-23

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

City of Hope与Israelita Albert Einstein签署协议以推动拉美地区的癌症治疗

2021-11-19

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Abrocitinib获得CHMP的积极意见，用于治疗成人中重度特应性皮炎

2022-01-05

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast

2021-09-01

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

2020年的CiteScore指标发布，你了解什么是CiteScore吗？

2022-01-18

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Clin Cancer Res：DNA甲基转移酶抑制剂Guadecitabine联合顺铂和吉西他滨治疗实体恶性肿瘤

2021-06-17

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Lancet：每日1次Upadacitinib单药治疗可显著改善中重度特应性皮炎患者临床症状

2022-03-23

科室
- - 订阅+
  - 更多科室
工具
服务